-
2024-518644-21-01
9
Advanced KRAS- Mutant Solid Tumours
-
2024-518786-10-01
4
Moderate to Severe Chronic Spontaneous Urticaria
-
2024-518835-13-00
5
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
-
2024-518871-74-00
4
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplific
-
2024-518990-33-00
11
Age-Associated Macular Degeneration
-
2024-519071-25-00
3
Advanced NSCLC
-
2024-519246-75-01
4
Patients With Muscle-Invasive Bladder Cancer
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519638-22-00
5
IgA nephropathy
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519673-18-00
4
Patients with localized renal cell carcinoma
-
2024-519772-10-00
4
Dry eye disease in patients with Graft versus Host disease patients
-
2024-519786-22-01
9
metastatic non-small cell lung cancer (NSCLC)
-
2024-519799-25-00
7
immune hyperactivation in COVID-19 patients and/or
acute respiratory d
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2024-519994-20-00
5
Agitation Associated with Alzheimer’s Disease
-
2024-520117-50-00
4
Atopic Dermatitis
-
2024-520125-36-00
3
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia
-
2024-520218-23-00
10
Pulmonary Arterial Hypertension
-
2024-520294-13-00
1
Cutaneous T-cell lymphomas (CTCL)
-
2024-520318-23-00
9
Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignan
-
2024-520336-14-00
5
Post-chemotherapy neutropenia with high risk of developing infection i
-
2024-520346-39-00
4
High cardiovascular risk in HIV patients
-
2025-520471-29-00
5
Locally advanced adenocarcinoma of the colon and upper rectum with mic